CRIS Current Research Information System

NANNI, JACOPO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 2.532
NA - Nord America 2.211
EU - Europa 1.454
AF - Africa 165
SA - Sud America 133
Continente sconosciuto - Info sul continente non disponibili 125
OC - Oceania 7
Totale 6.627
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.116
VN - Vietnam 638
SG - Singapore 620
IT - Italia 607
CN - Cina 597
HK - Hong Kong 190
GB - Regno Unito 149
SE - Svezia 132
KR - Corea 129
DE - Germania 119
NL - Olanda 103
BR - Brasile 93
BD - Bangladesh 92
IN - India 81
FR - Francia 66
FI - Finlandia 58
CA - Canada 48
CI - Costa d'Avorio 45
RU - Federazione Russa 45
JP - Giappone 42
IE - Irlanda 41
SC - Seychelles 33
ZA - Sudafrica 29
TG - Togo 26
ID - Indonesia 20
JO - Giordania 19
BG - Bulgaria 18
ES - Italia 17
PL - Polonia 17
AT - Austria 16
NG - Nigeria 16
PH - Filippine 16
TR - Turchia 15
MX - Messico 14
TH - Thailandia 14
TW - Taiwan 12
AR - Argentina 11
EC - Ecuador 11
CH - Svizzera 10
BE - Belgio 9
IQ - Iraq 9
EE - Estonia 8
UA - Ucraina 8
JM - Giamaica 7
PK - Pakistan 7
AU - Australia 6
CR - Costa Rica 6
GR - Grecia 6
IR - Iran 6
LT - Lituania 6
UZ - Uzbekistan 6
SV - El Salvador 5
TT - Trinidad e Tobago 5
AL - Albania 4
CL - Cile 4
MA - Marocco 4
PY - Paraguay 4
TN - Tunisia 4
VE - Venezuela 4
CO - Colombia 3
EG - Egitto 3
HR - Croazia 3
UY - Uruguay 3
AE - Emirati Arabi Uniti 2
AZ - Azerbaigian 2
CY - Cipro 2
CZ - Repubblica Ceca 2
ET - Etiopia 2
GT - Guatemala 2
HN - Honduras 2
KW - Kuwait 2
KZ - Kazakistan 2
MK - Macedonia 2
NI - Nicaragua 2
PT - Portogallo 2
RS - Serbia 2
SA - Arabia Saudita 2
SK - Slovacchia (Repubblica Slovacca) 2
AM - Armenia 1
CW - ???statistics.table.value.countryCode.CW??? 1
DZ - Algeria 1
GD - Grenada 1
HT - Haiti 1
HU - Ungheria 1
IL - Israele 1
KE - Kenya 1
KG - Kirghizistan 1
LC - Santa Lucia 1
LI - Liechtenstein 1
LK - Sri Lanka 1
MY - Malesia 1
NP - Nepal 1
NZ - Nuova Zelanda 1
PR - Porto Rico 1
QA - Qatar 1
UG - Uganda 1
XK - ???statistics.table.value.countryCode.XK??? 1
Totale 6.504
Salva come PNG Salva come JPEG
Città #
Singapore 460
Ashburn 267
Hefei 209
San Jose 207
Ho Chi Minh City 177
Hong Kong 164
Hanoi 144
Chandler 127
Bologna 118
Seoul 118
Southend 109
Dallas 100
Milan 73
Council Bluffs 67
New York 65
Santa Clara 62
Ann Arbor 54
Boardman 52
Beijing 50
Fairfield 50
Los Angeles 48
Helsinki 46
Abidjan 45
Chicago 41
Dublin 41
Princeton 39
Tokyo 34
Rome 30
Haiphong 28
Lauterbourg 26
Lomé 26
Phoenix 24
São Paulo 24
Houston 23
Seattle 22
Frankfurt am Main 21
Wilmington 21
Bengaluru 20
Buffalo 20
Da Nang 20
Amman 19
Cambridge 19
Turin 19
Johannesburg 18
Sofia 18
Amsterdam 17
Redondo Beach 15
Abeokuta 14
Florence 14
Jakarta 14
Nanjing 14
Woodbridge 14
Biên Hòa 13
Guangzhou 13
Falkenstein 12
Redmond 12
Toronto 12
Atlanta 11
Hải Dương 11
Modena 11
Montreal 11
Shanghai 11
Vienna 11
Warsaw 11
Bremen 10
Castel Maggiore 10
Munich 10
Nuremberg 10
Tianjin 10
London 9
Orem 9
Rimini 9
Brussels 8
Can Tho 8
Medford 8
Orlando 8
Zhengzhou 8
Bari 7
Bắc Ninh 7
Paris 7
Piscataway 7
Reggio Emilia 7
Washington 7
Westminster 7
Bangkok 6
Berlin 6
Catania 6
Chengdu 6
Denver 6
Lappeenranta 6
Madrid 6
Ninh Bình 6
Padova 6
Palermo 6
Quận Bình Thạnh 6
San Diego 6
San Francisco 6
Tongling 6
Brooklyn 5
Forlì 5
Totale 3.866
Salva come PNG Salva come JPEG
Nome #
Case Report: A Novel Activating FLT3 Mutation in Acute Myeloid Leukemia 309
AVALON: The Italian cohort study on real-life efficacy of hypomethylating agents plus venetoclax in newly diagnosed or relapsed/refractory patients with acute myeloid leukemia 271
Inotuzumab ozogamicin is effective in relapsed/refractory extramedullary B acute lymphoblastic leukemia 254
Assessment of liver stiffness measurement and ultrasound findings change during inotuzumab ozogamicin cycles for relapsed or refractory acute lymphoblastic leukemia 253
Safety Run-In and Part 1 of GIMEMA AML1718: Venetoclax Combined with FLAI as Induction Treatment in Non-Low-Risk AML 245
MEC (mitoxantrone, etoposide, and cytarabine) induces complete remission and is an effective bridge to transplant in acute myeloid leukemia 240
Integrated genomic-metabolic classification of acute myeloid leukemia defines a subgroup with NPM1 and cohesin/DNA damage mutations 231
Impact of Pre-Treatment Comorbidity Burden on Survival in Patients Receiving Venetoclax Plus Hypomethylating Agents 222
Copy number variants signature in two patients with relapsed acute promyelocytic leukemia 221
Long-Term Outcome After Adoptive Immunotherapy With Natural Killer Cells: Alloreactive NK Cell Dose Still Matters 221
Impact of infectious comorbidity and overall time of hospitalization in total outpatient management of acute myeloid leukemia patients following venetoclax and hypomethylating agents 217
Deficient necroptosis pathway as a negative prognostic factor in acute myeloid leukemia. 215
Microarray analysis to identifiy novel copy number alterations in acute myeloid leukemia 214
A venetoclax and azacitidine bridge-to-transplant strategy for NPM1-mutated acute myeloid leukaemia in molecular failure 211
NEXT GENERATION SEQUENCING FOR MINIMAL RESIDUAL DISEASE MEASUREMENT IN THE DAILY CLINICAL MANAGEMENT OF PH-NEGATIVE ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS IS FEASIBLE AND PROVIDES USEFUL CLINICAL DATA. 208
MHC-I Antigen Presentation Role in Immune Escape of Acute Myeloid Leukemia with High Burden of Genomic Aberration 202
An IDO1-related immune gene signature predicts overall survival in acute myeloid leukemia 201
Upfront intensive treatment analysis of the Italian Cohort Study on FLT3‐mutated AML patients (FLAM): The impact of a FLT3 inhibitor addition to standard chemotherapy in the real‐life setting 195
Gimema AML1718 Part 1: Planned Interim Analysis of a Safety Run-in and Phase 2 Open-Label Study of Venetoclax, Fludarabine, Idarubicin and Cytarabine (V-FLAI) in the Induction Therapy of Non Low-Risk Acute Myeloid Leukemia 191
Prognostic significance of alterations of pathways regulating autophagy in acute myeloid leukemia 188
The baseline comorbidity burden affects survival in elderly patients with acute myeloid leukemia receiving hypomethylating agents: Results from a multicentric clinical study 185
A Three-Genes Signature of Anti-Apoptotic Genes Showed Different Mechanisms in Preventing Apoptosis in Acute Myeloid Leukemia Cells and Could Provide an Useful Model to Establish the Proper BH3-Mimetich Drug or Combination 180
Tracking Response and Resistance in Acute Myeloid Leukemia through Single-Cell DNA Sequencing Helps Uncover New Therapeutic Targets 179
Long-Term Outcome After Adoptive Immunotherapy With Natural Killer Cells: Alloreactive NK Cell Dose Still Matters 173
Inotuzumab ozogamicin and donor lymphocyte infusion is a safe and promising combination in relapsed acute lymphoblastic leukemia after allogeneic stem cell transplant 168
Baseline cluster of differentiation 22 fluorescent intensity correlates with patient outcome after Inotuzumab Ozogamicin treatment 141
Safety profile and impact on survival of tyrosine kinase inhibitors versus conventional therapy in relapse or refractory FLT3 positive acute myeloid leukemia patients 140
Clinical Efficacy of Ponatinib in Philadelphia-Positive T-Cell Acute Lymphoblastic Leukemia with Extramedullary Involvement 124
Pharmacological inhibition of wip1 sensitizes acute myeloid leukemia cells to the mdm2 inhibitor nutlin-3a 124
Pharmacological Inhibition of WIP1 Sensitizes Acute Myeloid Leukemia Cells to the MDM2 Inhibitor Nutlin-3a 117
Venetoclax plus hypomethylating agents as effective bridge therapy to allogeneic stem cell transplant in relapsed/refractory acute myeloid leukaemia: A subanalysis of the AVALON study 105
Editorial: Precision medicine for acute myeloid leukemia 103
Venetoclax and hypomethylating agents in octogenarians and nonagenarians with acute myeloid leukemia 99
NPM1 and IDH1/2 Mutations Show Limited Prognostic Impact in Relapsed/Refractory AML: Evidence From the AVALON Cohort 76
Venetoclax plus hypomethylating agents as first salvage therapy for myeloid malignancies relapsing after allogeneic HSCT 68
Acute myeloid leukemia mutations: Therapeutic implications 62
IDH1/2 Mutations Are Maintained in a Subset of Patients with Acute Myeloid Leukemia in Complete Remission and Do Not Correlate with Residual Disease 54
A clinical experience with CAR-T cell therapy brexu-cel as salvage option for a Relapsed/Refractory patient with B-Cell Acute Lymphoblastic Leukemia in advanced disease stage.|Esperienza con CAR-T brexu-cel in paziente affetto da leucemia linfoblastica acuta B in fase avanzata di ricaduta/refrattarietà 20
Totale 6.627
Salva come PNG Salva come JPEG
Categoria #
all - tutte 17.732
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 17.732
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022356 0 0 0 27 29 17 10 50 20 42 98 63
2022/2023606 58 79 23 57 68 49 14 46 108 12 53 39
2023/2024277 8 25 14 34 20 52 11 28 17 22 33 13
2024/20251.061 45 149 72 76 69 49 116 55 24 114 91 201
2025/20263.348 361 455 234 275 193 138 328 101 676 229 168 190
2026/2027589 96 121 187 185 0 0 0 0 0 0 0 0
Totale 6.627